MESOBLAST LIMITED - Announcements

0.87%

$2.31

Market Cap $2.931B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

MSB	Results of Meeting		15/11/13	175.47KB	Share
MSB	CEO Presentation to Shareholders at AGM 2013		15/11/13	938.27KB	Share
MSB	Chairman's Address to Shareholders and Remuneration Strategy		15/11/13	595.96KB	Share
MSB	Improved Survival in Children with GvHD After Cell Therapy	PRICE SENSITIVE	14/11/13	110.33KB	Share
MSB	MPCs Induce Functional Recovery in Ischemic Stroke Model	PRICE SENSITIVE	11/11/13	99.23KB	Share
MSB	FDA Clears Phase 3 Heart Failure Trial	PRICE SENSITIVE	31/10/13	119.64KB	Share
MSB	MSBs Registration Plans for GVHD Cell Product in Japan	PRICE SENSITIVE	28/10/13	84.06KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/13	160.91KB	Share
MSB	Mesoblast, Intrexon and Ziopharm to Target Cancers	PRICE SENSITIVE	24/10/13	516.36KB	Share
MSB	Notice of Annual General Meeting/Proxy Form		15/10/13	229.71KB	Share
MSB	Annual Report to shareholders		11/10/13	2.92MB	Share
MSB	Investor Update		11/10/13	205.97KB	Share
MSB	Mesoblast Acquires Osiris' Cultured Stem Cell Business	PRICE SENSITIVE	11/10/13	124.44KB	Share
MSB	Spinal Fusion Trial to be Presented at Premier Spine Forum		19/09/13	373.08KB	Share
MSB	Appendix 3B		16/09/13	223.28KB	Share
MSB	Change of Director's Interest Notice		05/09/13	79.41KB	Share
MSB	Share Trading Policy		02/09/13	56.31KB	Share
MSB	Strong Cash Position Enables Execution of Late-Stage Trials		29/08/13	116.28KB	Share
MSB	2013 Financial Year Results Presentation		29/08/13	308.43KB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	29/08/13	741.39KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	01/08/13	185.86KB	Share
MSB	MSB Receives $4.3M Pipeline Funds from Australian Government	PRICE SENSITIVE	18/07/13	61.17KB	Share
MSB	MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy	PRICE SENSITIVE	26/06/13	130.63KB	Share
MSB	Key Mesenchymal Precursor Cell Patent Granted in Japan	PRICE SENSITIVE	05/06/13	102.76KB	Share
MSB	Circulation Research Publishes AMI Preclinical Trial Results	PRICE SENSITIVE	15/05/13	225.19KB	Share
MSB	Change in substantial holding		14/05/13	445.07KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	169.64KB	Share
MSB	Appendix 3B		30/04/13	201.13KB	Share
MSB	POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIR	PRICE SENSITIVE	22/04/13	386.62KB	Share
MSB	Initial Director's Interest Notice		22/04/13	9.45KB	Share
MSB	Director Appointment/Resignation		17/04/13	96.02KB	Share
MSB	CEO AWARDED INAUGURAL PONTIFICAL AWARD FOR INNOVATION		12/04/13	217.14KB	Share
MSB	Change in substantial holding		15/03/13	198.2KB	Share
MSB	MESOBLAST COMPLETES A$170M PRIVATE PLACEMENT		14/03/13	279.47KB	Share
MSB	Cleansing Notice Under Section 708A of the Corporations Act		14/03/13	161.12KB	Share
MSB	Appendix 3B		14/03/13	134.08KB	Share
MSB	Mesoblast Enters into Agreements to Raise A$170million	PRICE SENSITIVE	06/03/13	366.18KB	Share
MSB	Trading Halt	PRICE SENSITIVE	04/03/13	197.58KB	Share
MSB	FDA Agree on Use of MSBs Singapore Manufacturing Facility		13/02/13	67.85KB	Share
MSB	2013 1H Results: Strategic Update		11/02/13	125.25KB	Share
MSB	Half-Year Results & Strategic Update on Product Development	PRICE SENSITIVE	11/02/13	339.47KB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	11/02/13	369.39KB	Share
MSB	KEY MPC PATENTS GRANTED IN UNITED STATES AND CHINA	PRICE SENSITIVE	07/02/13	53.33KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	184.56KB	Share
MSB	Appendix 3B		31/01/13	232.5KB	Share
MSB	FDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS	PRICE SENSITIVE	30/01/13	63.82KB	Share
MSB	MSB Presents at JP Morgan US Healthcare Conference 2013		11/01/13	2.71MB	Share
MSB	Positive Results in Phase 2 Lumbar Spinal Fusion Trial	PRICE SENSITIVE	11/01/13	230.78KB	Share
MSB	Blood Cell Expansion Trial - New England Journal Of Medicine		13/12/12	911.48KB	Share
MSB	Results of Meeting		29/11/12	162.77KB	Share
MSB	Mesoblast Corporate Overview - CEO Message to AGM	PRICE SENSITIVE	29/11/12	233.18KB	Share
MSB	Chairman's speech and CEO presentation to 2012 AGM		29/11/12	1.46MB	Share
MSB	Key Manufacturing Agreement with FDA for Phase 3 Trials	PRICE SENSITIVE	20/11/12	130.26KB	Share
MSB	Mesoblast Market Update		19/11/12	127.9KB	Share
MSB	Price Query	PRICE SENSITIVE	15/11/12	166.61KB	Share
MSB	CEO Presentation to Bell Potter Life Sciences Conference		02/11/12	1.28MB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	185.41KB	Share
MSB	Appendix 3B		31/10/12	157.41KB	Share
MSB	Notice of Annual General Meeting/Proxy Form		29/10/12	208.24KB	Share
MSB	Annual Report to shareholders		29/10/12	5.86MB	Share
MSB	2012 Full Year Financial Results Presentation		22/08/12	929.82KB	Share
MSB	Strong Cash Position to Further Diversify Product Pipeline		22/08/12	146.71KB	Share
MSB	Preliminary Final Report	PRICE SENSITIVE	22/08/12	1.69MB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	174.29KB	Share
MSB	Rheumatoid Arthritis New Major Clinical Target for MSB	PRICE SENSITIVE	24/07/12	159.97KB	Share
MSB	Response to ASXPrice Query	PRICE SENSITIVE	18/06/12	190.73KB	Share
MSB	MSB Provides Corporate Strategy For Neurologic Product	PRICE SENSITIVE	08/06/12	1MB	Share
MSB	Final Director's Interest Notice		16/05/12	10.57KB	Share
MSB	Initial Director's Interest Notice		16/05/12	9.5KB	Share
MSB	Director Appointment		10/05/12	120.91KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	189.32KB	Share
MSB	Intervertebral Disc Repair Phase 2 Trial Update	PRICE SENSITIVE	17/04/12	129.89KB	Share
MSB	Mesoblast Update to Credit Suisse Asia Investment Conference		26/03/12	1.51MB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/12	553.2KB	Share
MSB	2012 Half Year Results Investor Presentation		27/02/12	580.94KB	Share
MSB	FORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER		22/02/12	53.17KB	Share
MSB	Company Secretary Appointment/Resignation		09/02/12	106.82KB	Share
MSB	Appendix 3B		09/02/12	187.31KB	Share
MSB	FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes	PRICE SENSITIVE	31/01/12	151.27KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	12/01/12	130.08KB	Share
MSB	Appendix 3B		12/01/12	190.13KB	Share
MSB	Presentation to 30th JP Morgan Healthcare Conference in USA		12/01/12	1.11MB	Share
MSB	FORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER		09/12/11	69.29KB	Share
MSB	Results of Meeting		24/11/11	135.56KB	Share
MSB	Corporate Strategy Key to Mesoblast's Success		24/11/11	149.73KB	Share
MSB	Chairman's Address and CEO's Presentation to Shareholders		24/11/11	839.87KB	Share
MSB	Positive Outcome From FDA Meeting For Diabetes Program	PRICE SENSITIVE	22/11/11	213.39KB	Share
MSB	Presentation to the American Heart Association		15/11/11	5.18MB	Share
MSB	Positive Heart Failure Trial Results Presented to AHA	PRICE SENSITIVE	15/11/11	226.43KB	Share
MSB	Positive Results Using Adult Stem Cells for Type 2 Diabetes	PRICE SENSITIVE	10/11/11	795.25KB	Share
MSB	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/11	132.31KB	Share
MSB	Response to ASX Price Query Letter	PRICE SENSITIVE	28/10/11	179.75KB	Share
MSB	Annual Report to shareholders		24/10/11	2.4MB	Share
MSB	Notice of Annual General Meeting/Proxy Form		24/10/11	648.04KB	Share
MSB	Clearance for First Phase 2 Clinical Trial for Eye Diseases	PRICE SENSITIVE	24/10/11	228.55KB	Share
MSB	Licensing Executives Society Deals of Distinction Award	PRICE SENSITIVE	20/10/11	198.97KB	Share
MSB	MSB and Lonza form strategic global manufacturing alliance	PRICE SENSITIVE	27/09/11	29.85KB	Share
MSB	FORM 604 CHANGE OF INTERESTS OF SUB HOLDER		15/09/11	71.51KB	Share
MSB	First European Trial for Heart Attack Treatment Cleared	PRICE SENSITIVE	05/09/11	227.7KB	Share
MSB	Full Year Audited Statutory Accounts		31/08/11	598.76KB	Share

MSBResults of Meeting
15/11/13		175.47KB	Share
MSBCEO Presentation to Shareholders at AGM 2013
15/11/13		938.27KB	Share
MSBChairman's Address to Shareholders and Remuneration Strategy
15/11/13		595.96KB	Share
MSBImproved Survival in Children with GvHD After Cell Therapy
14/11/13	PRICE SENSITIVE	110.33KB	Share
MSBMPCs Induce Functional Recovery in Ischemic Stroke Model
11/11/13	PRICE SENSITIVE	99.23KB	Share
MSBFDA Clears Phase 3 Heart Failure Trial
31/10/13	PRICE SENSITIVE	119.64KB	Share
MSBMSBs Registration Plans for GVHD Cell Product in Japan
28/10/13	PRICE SENSITIVE	84.06KB	Share
MSBAppendix 4C - quarterly
25/10/13	PRICE SENSITIVE	160.91KB	Share
MSBMesoblast, Intrexon and Ziopharm to Target Cancers
24/10/13	PRICE SENSITIVE	516.36KB	Share
MSBNotice of Annual General Meeting/Proxy Form
15/10/13		229.71KB	Share
MSBAnnual Report to shareholders
11/10/13		2.92MB	Share
MSBInvestor Update
11/10/13		205.97KB	Share
MSBMesoblast Acquires Osiris' Cultured Stem Cell Business
11/10/13	PRICE SENSITIVE	124.44KB	Share
MSBSpinal Fusion Trial to be Presented at Premier Spine Forum
19/09/13		373.08KB	Share
MSBAppendix 3B
16/09/13		223.28KB	Share
MSBChange of Director's Interest Notice
05/09/13		79.41KB	Share
MSBShare Trading Policy
02/09/13		56.31KB	Share
MSBStrong Cash Position Enables Execution of Late-Stage Trials
29/08/13		116.28KB	Share
MSB2013 Financial Year Results Presentation
29/08/13		308.43KB	Share
MSBPreliminary Final Report
29/08/13	PRICE SENSITIVE	741.39KB	Share
MSBAppendix 4C - quarterly
01/08/13	PRICE SENSITIVE	185.86KB	Share
MSBMSB Receives $4.3M Pipeline Funds from Australian Government
18/07/13	PRICE SENSITIVE	61.17KB	Share
MSBMSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy
26/06/13	PRICE SENSITIVE	130.63KB	Share
MSBKey Mesenchymal Precursor Cell Patent Granted in Japan
05/06/13	PRICE SENSITIVE	102.76KB	Share
MSBCirculation Research Publishes AMI Preclinical Trial Results
15/05/13	PRICE SENSITIVE	225.19KB	Share
MSBChange in substantial holding
14/05/13		445.07KB	Share
MSBAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	169.64KB	Share
MSBAppendix 3B
30/04/13		201.13KB	Share
MSBPOSITIVE INTERIM RESULTS IN PHASE 2 TRIAL FOR DISC REPAIR
22/04/13	PRICE SENSITIVE	386.62KB	Share
MSBInitial Director's Interest Notice
22/04/13		9.45KB	Share
MSBDirector Appointment/Resignation
17/04/13		96.02KB	Share
MSBCEO AWARDED INAUGURAL PONTIFICAL AWARD FOR INNOVATION
12/04/13		217.14KB	Share
MSBChange in substantial holding
15/03/13		198.2KB	Share
MSBMESOBLAST COMPLETES A$170M PRIVATE PLACEMENT
14/03/13		279.47KB	Share
MSBCleansing Notice Under Section 708A of the Corporations Act
14/03/13		161.12KB	Share
MSBAppendix 3B
14/03/13		134.08KB	Share
MSBMesoblast Enters into Agreements to Raise A$170million
06/03/13	PRICE SENSITIVE	366.18KB	Share
MSBTrading Halt
04/03/13	PRICE SENSITIVE	197.58KB	Share
MSBFDA Agree on Use of MSBs Singapore Manufacturing Facility
13/02/13		67.85KB	Share
MSB2013 1H Results: Strategic Update
11/02/13		125.25KB	Share
MSBHalf-Year Results & Strategic Update on Product Development
11/02/13	PRICE SENSITIVE	339.47KB	Share
MSBHalf Yearly Report and Accounts
11/02/13	PRICE SENSITIVE	369.39KB	Share
MSBKEY MPC PATENTS GRANTED IN UNITED STATES AND CHINA
07/02/13	PRICE SENSITIVE	53.33KB	Share
MSBAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	184.56KB	Share
MSBAppendix 3B
31/01/13		232.5KB	Share
MSBFDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS
30/01/13	PRICE SENSITIVE	63.82KB	Share
MSBMSB Presents at JP Morgan US Healthcare Conference 2013
11/01/13		2.71MB	Share
MSBPositive Results in Phase 2 Lumbar Spinal Fusion Trial
11/01/13	PRICE SENSITIVE	230.78KB	Share
MSBBlood Cell Expansion Trial - New England Journal Of Medicine
13/12/12		911.48KB	Share
MSBResults of Meeting
29/11/12		162.77KB	Share
MSBMesoblast Corporate Overview - CEO Message to AGM
29/11/12	PRICE SENSITIVE	233.18KB	Share
MSBChairman's speech and CEO presentation to 2012 AGM
29/11/12		1.46MB	Share
MSBKey Manufacturing Agreement with FDA for Phase 3 Trials
20/11/12	PRICE SENSITIVE	130.26KB	Share
MSBMesoblast Market Update
19/11/12		127.9KB	Share
MSBPrice Query
15/11/12	PRICE SENSITIVE	166.61KB	Share
MSBCEO Presentation to Bell Potter Life Sciences Conference
02/11/12		1.28MB	Share
MSBAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	185.41KB	Share
MSBAppendix 3B
31/10/12		157.41KB	Share
MSBNotice of Annual General Meeting/Proxy Form
29/10/12		208.24KB	Share
MSBAnnual Report to shareholders
29/10/12		5.86MB	Share
MSB2012 Full Year Financial Results Presentation
22/08/12		929.82KB	Share
MSBStrong Cash Position to Further Diversify Product Pipeline
22/08/12		146.71KB	Share
MSBPreliminary Final Report
22/08/12	PRICE SENSITIVE	1.69MB	Share
MSBAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	174.29KB	Share
MSBRheumatoid Arthritis New Major Clinical Target for MSB
24/07/12	PRICE SENSITIVE	159.97KB	Share
MSBResponse to ASXPrice Query
18/06/12	PRICE SENSITIVE	190.73KB	Share
MSBMSB Provides Corporate Strategy For Neurologic Product
08/06/12	PRICE SENSITIVE	1MB	Share
MSBFinal Director's Interest Notice
16/05/12		10.57KB	Share
MSBInitial Director's Interest Notice
16/05/12		9.5KB	Share
MSBDirector Appointment
10/05/12		120.91KB	Share
MSBAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	189.32KB	Share
MSBIntervertebral Disc Repair Phase 2 Trial Update
17/04/12	PRICE SENSITIVE	129.89KB	Share
MSBMesoblast Update to Credit Suisse Asia Investment Conference
26/03/12		1.51MB	Share
MSBHalf Yearly Report and Accounts
27/02/12	PRICE SENSITIVE	553.2KB	Share
MSB2012 Half Year Results Investor Presentation
27/02/12		580.94KB	Share
MSBFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER
22/02/12		53.17KB	Share
MSBCompany Secretary Appointment/Resignation
09/02/12		106.82KB	Share
MSBAppendix 3B
09/02/12		187.31KB	Share
MSBFDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
31/01/12	PRICE SENSITIVE	151.27KB	Share
MSBAppendix 4C - quarterly
12/01/12	PRICE SENSITIVE	130.08KB	Share
MSBAppendix 3B
12/01/12		190.13KB	Share
MSBPresentation to 30th JP Morgan Healthcare Conference in USA
12/01/12		1.11MB	Share
MSBFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER
09/12/11		69.29KB	Share
MSBResults of Meeting
24/11/11		135.56KB	Share
MSBCorporate Strategy Key to Mesoblast's Success
24/11/11		149.73KB	Share
MSBChairman's Address and CEO's Presentation to Shareholders
24/11/11		839.87KB	Share
MSBPositive Outcome From FDA Meeting For Diabetes Program
22/11/11	PRICE SENSITIVE	213.39KB	Share
MSBPresentation to the American Heart Association
15/11/11		5.18MB	Share
MSBPositive Heart Failure Trial Results Presented to AHA
15/11/11	PRICE SENSITIVE	226.43KB	Share
MSBPositive Results Using Adult Stem Cells for Type 2 Diabetes
10/11/11	PRICE SENSITIVE	795.25KB	Share
MSBAppendix 4C - quarterly
31/10/11	PRICE SENSITIVE	132.31KB	Share
MSBResponse to ASX Price Query Letter
28/10/11	PRICE SENSITIVE	179.75KB	Share
MSBAnnual Report to shareholders
24/10/11		2.4MB	Share
MSBNotice of Annual General Meeting/Proxy Form
24/10/11		648.04KB	Share
MSBClearance for First Phase 2 Clinical Trial for Eye Diseases
24/10/11	PRICE SENSITIVE	228.55KB	Share
MSBLicensing Executives Society Deals of Distinction Award
20/10/11	PRICE SENSITIVE	198.97KB	Share
MSBMSB and Lonza form strategic global manufacturing alliance
27/09/11	PRICE SENSITIVE	29.85KB	Share
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
15/09/11		71.51KB	Share
MSBFirst European Trial for Heart Attack Treatment Cleared
05/09/11	PRICE SENSITIVE	227.7KB	Share
MSBFull Year Audited Statutory Accounts
31/08/11		598.76KB	Share

REFRESH

First 7 8 9 10 11

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.31		Change 0.020(0.87%)		Mkt cap ! $2.931B

Open	High	Low	Value	Volume
$2.31	$2.33	$2.31	$878.5K	379.1K

Buyers (Bids)

No.	Vol.	Price($)
18	34074	$2.30

Sellers (Offers)

Price($)	Vol.	No.
$2.31	13421	8

View Market Depth

No.	Vol.	Price($)
16	43746	2.300
11	73003	2.290
14	111603	2.280
11	64492	2.270
8	75320	2.260

Price($)	Vol.	No.
2.310	3980	6
2.320	33702	13
2.330	53509	12
2.340	72939	12
2.350	173887	15

Last trade - 10.12am 13/08/2025 (20 minute delay)


Last $2.33		Change 0.020 ( 1.84 %)
Open	High	Low	Volume
$2.32	$2.33	$2.31	63487
Last updated 10.31am 13/08/2025 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories